More on Dynavax (DVAX): Q1 misses on bottom line estimates as the company logs higher R&D...

|About: Dynavax Technologies Corpor... (DVAX)|By:, SA News Editor

More on Dynavax (DVAX): Q1 misses on bottom line estimates as the company logs higher R&D and SG&A expenses and revenue declines slightly Y/Y. Total expenses rose by 21% over the prior year period, due primarily to the purchase of a Heplisav component as well as severance expenses, including non-cash stock-based compensation charges. Shares -1.7% AH.